Recent Updates
Recently added Catalysts
ATYR

aTyr Pharma to Webcast Conference Call Reporting First Quarter 2020 Financial Results

Key Takeaway: SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results

Full Press Release Details

SAN DIEGO, May 06, 2020 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report first quarter 2020 financial results and provide a corporate update after the market close on Tuesday, May 12, 2020.
Conference Call and Webcast Details:
Tuesday, May 12th @ 5:00 p.m. EDT / 2:00 p.m. PDT
Domestic:  844-358-9116
International:  209-905-5951
Conference ID:  1375605
aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases. For more information, please visit http://www.atyrpharma.com.
Contact:
Joyce Allaire
Managing Director, LifeSci Advisors, LLC
jallaire@lifesciadvisors.com

Tags

Last updated: May 6, 2020